The study drives attention to the 'heterogeneous' nature of dementia that can involve people at any age.
Alzheimer's disease. Exploring the mysteries of young people with Alzheimer's disease may become one of the most challenging scientific questions of the future," the authors said.The authors stated that almost all Alzheimer's disease patients younger than 30 have pathological gene mutations. Before this diagnosis, the youngest patient with Alzheimer's was 21 years old.
The person eventually dropped out of high school as he could not finish his homework, could not recall if he had eaten, and frequently lost his personal belongings.George Perry, a professor at the University of Texas at San Antonio and who was not involved in the study, toldthat further research was required to understand if Alzheimer's disease, like dementia, in youth was becoming more common.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Neurologists Diagnose The Youngest Case of Alzheimer's Ever ReportedNeurologists at a memory clinic in China have diagnosed a 19-year-old with what they believe to be Alzheimer's disease, making him the youngest person to be diagnosed with the condition in the world.
Read more »
New Blood Test Detects Alzheimer’s Disease 3.5 Years Before Clinical DiagnosisA blood-based test could be used to predict the risk of Alzheimer’s disease up to 3.5 years before clinical diagnosis according to new research from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London. The study, published on January 27 in the journal Brain
Read more »
69-year-old man with Alzheimer’s disease missing from BellevueBellevue police are asking for the public’s help to find a man with Alzheimer’s disease who walked away from his home on Monday morning.
Read more »
Biogen sees modest 2023 revenue from Alzheimer's disease drugBiogen Inc said on Wednesday that Alzheimer's disease drug Leqembi would bring in modest revenue for the year although it might not be enough to offset costs tied to its launch.
Read more »
Biogen CEO bets on Alzheimer's drug, pipeline to return to growthBiogen Inc Chief Executive Officer Christopher Viehbacher said on Wednesday he is banking on high-profile launches of Alzheimer's disease treatment Leqembi and depression drug zuranolone, as well as deals, to help the company return to revenue growth.
Read more »
China shifts COVID origin blame after WHO abandons study into virus beginningsThe People's Republic of China is dismissing accusations of impeding the World Health Organization's investigation into the origins of the COVID-19 pandemic.
Read more »